Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
doi:10.1136/jcp.56.12.924 Hamaguchi Y, Kondoh T, Fukuda M, et al
Decrease dose if: Experiencing consistent side effects (headaches, fatigue, GI disturbance), achieving satisfactory results at current dose with no need for escalation, or cost considerations favor using minimum effective dose
Those include Crohn's disease, celiac disease, Graves' disease, and lupus
Australia, Canada, and EU In Australia, AOD9604 is classified as a prescription-only medication by the Therapeutic Goods Administration (TGA) (Poisons Standard Appendix D lists AOD9604
What we don't have is a Phase 3 randomized controlled trial showing that human patients on AOD-9604 heal fractures faster, achieve higher bone density, or return to function earlier than controls
